Previous 10 | Next 10 |
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of today's top gainers. The company's shares have moved 0.41% on the day to $971.98. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The compa...
2024-03-13 13:05:07 ET Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference March 13, 2024 10:40 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Christopher Fenimore - Chief Financial Officer Conference ...
2024-03-13 10:15:02 ET Morgan Stanley analyst issues OVERWEIGHT recommendation for REGN on March 13, 2024 08:51AM ET. The previous analyst recommendation was Overweight. REGN was trading at $970.57 at issue of the analyst recommendation. The overall analyst consensus : B...
TARRYTOWN, N.Y. and WASHINGTON, D.C., March 12, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Society for Science (the Society) announced that Achyuta Rajaram, 17, of Exeter, NH, won the top award in the Regeneron Science Talent Searc...
2024-03-12 13:35:31 ET Regeneron Pharmaceuticals, Inc. (REGN) Barclays 26th Annual Global Healthcare Conference Transcript March 12, 2024, 11:15 AM ET Executives Chris Fenimore - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Analysts ...
2024-03-11 07:52:45 ET Regeneron Pharmaceuticals ( NASDAQ: REGN ) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high cholesterol.... Read the full article on Seeking A...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowe...
2024-03-10 13:00:53 ET More on the markets S&P 500: Time To Hedge, Here's How How The S&P 500 Could Actually Be Closer To 4,200 Than 5,000 SPDR S&P 500 ETF And Invesco QQQ Trust: Almost All Investors Are Crowded Into The Same Side Of The Boat Cata...
2024-03-09 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-08 08:15:00 ET Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF , which tracks an industry index, is up by nearly 13% year to date. Still, it's too...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an a...
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood ...
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation Paris and Tarrytown, NY May 31, 2024. The...